Eli Lilly (LLY) said Wednesday its Surmount-5 phase 3b clinical study showed that Zepbound provided a 47% "greater relative weight loss" in comparison to Novo Nordisk's (NVO) Wegovy.
Zepbound, Eli Lilly's weight-loss drug, resulted in a "superior" weight reduction of 20.2% against Wegovy's 13.7%, the company added.
Eli Lilly's stock rose 2.3% in recent Wednesday premarket activity, while Novo Nordisk's shares were little changed.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。